Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer IngelheimNov 29, 2022
Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respiratory Society International Congress 2022Sep 6, 2022
Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual MeetingApr 11, 2022